Abstract: The invention relates to an enzyme-containing gel composition capable of controlling enzymatic release and increasing the enzymatic activity level. When the composition includes at least one enzyme derived from Antarctic krill, it is efficient in cleansing wounds and accelerating healing, achieved in significant part by a glycol and/or glycerol gel capable of sustaining enzymatic release and/or enzymatic activity. The krill enzyme-containing gel may also be used to correct skin disorders, sterilize instruments, and facilitate transplants and treating fungal infections, bacterial infections, parasitic infections, hemorrhoids, corneal scarring, dental plaque, acne, cystic fibrosis, blood clots, immune disorders, autoimmune diseases and cancer.

Abstract: The invention provides a method and composition for treatment of lesions associated with viral infections, such as human Herpes simplex, by applying to the lesions an effective amount of a topical composition comprising: propolis extract in from about 0.5 to 10%, preferably about 1 to 8%, by weight; a skin protectant in from about 0.5% to 50% by weight; a penetration enhancing agent in from about 5 to 30%, preferably 5 to 25%, by weight; and an emulsifier in from about 1 to 20% by weight. The subject compositions possess enhanced activity in the treatment of such lesions in that they stop the outbreak at the stage of progression when they are applied and promote full healing, generally within 36 to 48 hours.

Abstract: The invention provides a method and composition for treatment of lesions associated with viral infections, such as human Herpes simplex, by applying to the lesions an effective amount of a topical composition comprising: propolis extract in from about 0.5 to 10%, preferably about 1 to 8%, by weight; a skin protectant in from about 0.5% to 50% by weight; a penetration enhancing agent in from about 5 to 30%, preferably 5 to 25%, by weight; and an emulsifier in from about 1 to 20% by weight. The subject compositions possess enhanced activity in the treatment of such lesions in that they stop the outbreak at the stage of progression when they are applied and promote full healing, generally within 36 to 48 hours.

Abstract: The invention provides a method and composition for treatment of Aphthous Stomatitis by applying thereto an effective amount of a composition comprising from about 0.5 to 25%, preferably about 0.5 to 10%, by weight of propolis extract in a suitable vehicle for topical administration to the oral mucosa. The compositions preferably contain a protectant, an emulsifier and suitable flavoring agents. The subject compositions possess enhanced activity in the treatment of aphthous ulcers in that they stop the progression at the stage when they are applied and promote full healing, generally within 36 to 48 hours.

Abstract: This invention relates to substituted 5-pyrimidinesulfonamides, pharmaceutically acceptable salts thereof and to processes for synthesis thereof. Other aspects of the invention concern pharmaceutical compositions containing an instant compound as active ingredient and methods of treatment where there is an indicated need for an antihypertensive and/or diuretic agent.

Abstract: This invention relates to novel [(substituted naphthalenyl)alkyl]-3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical compositions thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.

Abstract: This invention relates to novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides, to the processes for their preparation, to methods for using the compounds, and to pharmaceutical preparations thereof. The compounds have pharmaceutical properties which render them beneficial for the treatment of diabetes mellitus and associated conditions.

Abstract: This invention relates to substituted 5-pyrimidinesulfonamides, pharmaceutically acceptable salts thereof and to processes for synthesis thereof. Other aspects of the invention concern pharmaceutical compositions containing an instant compound as active ingredient and methods of treatment where there is an indicated need for an antihypertensive and/or diuretic agent.

Abstract: A process for resolving a racemic modification of .beta.-adrenergic aryl- or hetaryl-oxypropanolamines such as (.+-.)-2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-)-1,1-dimethylethyl]amino]propox y]benzonitrile into its individual enantiomers is described. The process comprises converting the racemic modification into a pair of diastereomeric urea derivativesby reaction with a chiral aralkylisocyanate; separation into the individual diastereomers; and facile regeneration of the starting amine by cleavage of the intermediate urea compound using hydrazine. This final step is improved by the addition of an .alpha.-keto carboxylic acid, such as pyruvic acid, which functions as a scavenger of nucleophilic by-products.

Abstract: Dipeptides having the formula ##STR1## wherein A is halogen, hydrogen, lower alkyl, or lower alkoxy; B is hydrogen or lower alkyl, or A and B are taken together to form an ortho-methylene or ethylene bridge; R is hydrogen, lower alkyl, or phenylalkyl; and X.sup.1 and X.sup.2 are independently chosen from hydroxy or lower alkoxy; are inhibitors of angiotensin-converting enzyme and can be used for the treatment of hypertension in mammals.

Abstract: Novel phthalimide intermediates are reduced to 5-sulfamoyl-6-halo-3-oxoisoindole compounds bearing a substituted 1-phenylalkyl-4-piperidinyl moiety as the isoindole N-substitutent. Preferred compounds such as 6-chloro-2,3-dihydro-3-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-1H-isoindole -5-sulfonamide exhibit diuretic and antihypertensive properties.

Abstract: The invention is generally concerned with isoindolinyl-alkylpiperazine compounds generally characterized by the formula ##STR1## wherein X is halogen or trifluoromethyl; n is an integer ranging from 2 to 5; Y is ##STR2## in which R.sub.1 is hydrogen, halogen, lower alkyl, lower alkoxy, trifluoromethyl, cyano; R.sub.2 is hydrogen, halogen, lower alkyl, lower alkoxy; and R.sub.3 is hydrogen, cyano. These compounds are useful as diuretic and/or antihypertensive agents.

Abstract: The invention provides 3-oxoisoindole compounds useful as diuretics of the general formula ##STR1## wherein X is halogen or trifluoromethyl, A is alkylene (C.sub.2 -C.sub.4), R.sub.1 is alkyl, R.sub.2 is alkyl or phenylalkyl, or R.sub.1 and R.sub.2 taken together with nitrogen are piperidino, morpholino or pyridinyl.

Abstract: Novel phthalimide intermediates are reduced to 5-sulfamoyl-6-halo-3-oxoisoindole compounds bearing a substituted 1-phenylalkyl-4-piperidinyl moiety as the isoindole N-substituent. Preferred compounds such as 6-chloro-2,3-dihydro-3-oxo-2-[1-(phenylmethyl)-4-piperidinyl]-1H-isoindole -5-sulfonamide exhibit diuretic and antihypertensive properties.

Abstract: A process for resolving a racemic modification of .beta.-adrenergic aryl- or hetaryl-oxypropanolamines such as (.+-.)-2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy] benzonitrile into its individual enantiomers is described. The process comprises converting the racemic modification into a pair of diastereomeric urea derivatives by reaction with a chiral aralkylisocyanate; separation into the individual diastereomers; and facile regeneration of the starting amine by cleavage of the intermediate urea compound using hydrazine. This final step is improved by the addition of an .alpha.-keto carboxylic acid, such as pyruvic acid, which functions as a scavenger of nucleophilic by-products.